Related Experiment Video

Updated: Feb 19, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.7K

Management of acute severe ulcerative colitis in children

Vei Shaun Siow1, Riha Bhatt2, Kevin P Mollen3

  • 1Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Seminars in Pediatric Surgery
|November 12, 2017
PubMed

Insights

The incidence of pediatric ulcerative colitis (UC) is increasing, with children often experiencing more severe disease. This review covers the unique epidemiology, diagnosis, and management of acute severe ulcerative colitis (ASUC) in children.

Area of Science:

  • Pediatric gastroenterology
  • Inflammatory Bowel Disease (IBD) research
  • Colorectal disease in children

Background:

  • Pediatric ulcerative colitis (UC) incidence is rising globally.
  • Children with UC frequently exhibit a more severe disease phenotype than adults.
  • Over one-third of pediatric UC cases require hospitalization for acute severe ulcerative colitis (ASUC).

Purpose of the Study:

  • To review the distinct characteristics of pediatric acute severe ulcerative colitis (ASUC).
  • To discuss the epidemiology, diagnostic challenges, and management strategies for pediatric ASUC.
  • To highlight the diagnostic difficulties in differentiating UC from Crohn's disease in pediatric patients with colitis.

Main Methods:

  • Literature review focusing on pediatric ulcerative colitis and acute severe ulcerative colitis.
  • Synthesis of current data on epidemiology, diagnosis, and treatment modalities.
  • Analysis of challenges in pediatric IBD diagnosis limited to the colon.

Main Results:

  • Pediatric ASUC presents unique epidemiological trends and disease severity.
  • Diagnostic uncertainty between UC and Crohn's disease is common in pediatric patients.
  • Management strategies for pediatric ASUC involve both medical and surgical interventions.

Conclusions:

  • Pediatric ASUC is a growing concern requiring specialized attention.
  • Accurate diagnosis and tailored management are crucial for improving outcomes in pediatric UC.
  • Further research into pediatric IBD is needed to address diagnostic and therapeutic gaps.

Keywords:
Pediatric Ulcerative Colitis Activity Index (PUCAI)Pediatric inflammatory bowel diseaseToxic megacolonUlcerative colitis

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.8K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.9K

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
728
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
547
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
546
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.2K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
817
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
538